Using immune therapy and antibiotics to treat severe inflammation in older patients with sepsis and ARDS.
Official title: An Innovative Immune Therapy with Antibiotics to Treat Deadly Excess Inflammation in Sepsis and ARDS Induced from Severe Bacterial Infection in Geriatric Patients
Funded at Bioprovar Corporation · NIH-10300896 · Data updated 2026-11-12
This study is looking at a new way to help older adults with sepsis and severe breathing problems by using a mix of immune therapy and antibiotics, focusing on a special immune receptor that might help reduce harmful inflammation and improve their chances of recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Bioprovar Corporation NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 30, 2021 |
| Project end | June 30, 2025 |
| Funding year | 2021 |
| Award (this year) | $376,045 |
| NIH project number | 1U44AG074105-01 |
| Project ID | NIH-10300896 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are geriatric patients diagnosed with sepsis or ARDS due to severe bacterial infections.
✕Less likely to help
Patients who are not elderly or those without a diagnosis of sepsis or ARDS may not benefit from this research.
What this research studies
This research investigates a novel approach to treating sepsis and acute respiratory distress syndrome (ARDS) in geriatric patients by combining immune therapy with antibiotics. The study focuses on the role of TREM1, a receptor involved in the immune response, and its splice variant TREM1-sv, which may help regulate excessive inflammation caused by bacterial infections. By targeting this pathway, the research aims to improve survival rates in older adults suffering from these life-threatening conditions. Patients will be monitored for their response to this innovative treatment strategy.
Why it matters
Potential benefit: If successful, this research could significantly increase survival rates for elderly patients suffering from sepsis and ARDS.
How similar studies have gone: Previous research has shown promising results in targeting the TREM1 pathway for reducing inflammation, indicating potential for success in this novel approach.
Where this research is happening
-
Bioprovar Corporation
Houston, United States Active
Researchers
- Principal investigator: Roussel, Eugene — Bioprovar Corporation
- Study coordinator: Roussel, Eugene
Related research
Other NIH-funded projects on the same topics.
-
Innovative immune therapy with antibiotics to treat deadly inflammation in sepsis and ARDS in older adults
A new approach combines an antibiotic strategy with a special immune-based treatment to help older patients who have sepsis or ARDS from severe bacterial infection.
-
A new immune-blocking therapy plus antibiotics for severe sepsis and ARDS in older adults
This project is trying a treatment that restores a natural TREM1 blocker together with antibiotics to help older adults with life-threatening bacterial sepsis or ARDS.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Understanding ARDS, pneumonia, and sepsis: a big study to map how illness and recovery unfold
A large patient study at the University of Pennsylvania will follow adults with ARDS, pneumonia, or sepsis to learn how these conditions progress and recover over time.
-
Coordination and data sharing for ARDS, pneumonia, and sepsis research
A national collaborative effort to improve how researchers study ARDS, pneumonia, and sepsis by coordinating centers, data collection, and analyses.
-
Molecular profiling of ARDS, pneumonia, and sepsis in adults using advanced sequencing
A research team at four California hospitals will study adults with ARDS, pneumonia, or sepsis to identify molecular patterns in their illness using genetic sequencing.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.